MedPath

The Effects of Breakfast Size on Hormonal Profile in Adults With Type 2 Diabetes Mellitus

Not Applicable
Conditions
Diabetes Mellitus, Type 2
Registration Number
NCT01178723
Lead Sponsor
Wolfson Medical Center
Brief Summary

Studies has found a connection between breakfast consumption and obesity and obesity-related complications, but only few studies examined the effect of breakfast size.

The purpose of this study is to examine the effect of breakfast size on several parameters in adults with Type 2 diabetes mellitus.

Detailed Description

The prevalence of obesity has rapidly increased during recent decades, while the prevalence of skipping breakfast has increased.

Several studies have reported inverse relationships between the consumption of breakfast and BMI and weight gain. A study that examined the effect of breakfast size, found that an increased percentage of daily energy consumed at breakfast was associated with relatively lower weight gain. Preliminary results of clinical research (unpublished) show a connection between a large breakfast and weight loss and increased feeling of satiety throughout the day.

The purpose of this study is to examine the effect of breakfast size on blood glucose balance, and its correlation with hormonal profile (including appetite hormones), adipokines and pro-inflammatory cytokines, weight and body composition and lipid profile in adults with type 2 diabetes.

The study will use a randomized-controlled, non-blinded, prospective design, including 48 participants with type 2 diabetes, who are not insulin dependent.

The research group will receive instructions to eat a large breakfast compared with the control group that will receive instructions to eat a small breakfast.

The estimated duration of the study is about three months.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
48
Inclusion Criteria
  • Men and women ages: 30-70
  • Type 2 diabetics who are treated on a diet and / or pills
  • Patients who receive a stable drug treatment (no change in the type/dosage of drugs during the three months preceding the research)
  • Obese or overweight (35> BMI> 25)
  • Patients who did not participate in another research for at least 30 days
  • Patients who agree to sign a consent form and participate in research
  • Patients with high compliance.
Exclusion Criteria
  • Patients under the age 30 or over 70
  • Type 1 I diabetics
  • Patients who are insulin dependent
  • Type 2 diabetics who are treated with injections
  • BMI less than 25 or BMI over 35
  • Patients who had Bariatric surgery
  • Patients with food absorption disorders
  • Active malignant disease
  • Thyroid function disorder
  • Active psychiatric illness
  • Pregnancy / breastfeeding

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
blood glucose balancethree months

HBA1C, C-peptid, insulin, glucose, HOMA-IR, Glycomark

Secondary Outcome Measures
NameTimeMethod
anthropometric parametersthree months

weight, height, body composition

Adipokines and hormonesthree months

insulin, leptin, ghrelin, adiponectin, GLP-1, cortisol

pro-inflammatory cytokinesthree months

TNF-α, IL-6, MCP-1, CRP

lipid profilethree months

triglycerides, cholesterol, LDL, HDL

Trial Locations

Locations (1)

Diabetes Unit, Wolfson Medical Center

🇮🇱

Holon, Israel

© Copyright 2025. All Rights Reserved by MedPath